Marinus Pharmaceuticals, Inc.
MRNS · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $146,191 | $38,877 | $108,991 | $83,174 |
| - Cash | $120,572 | $240,551 | $122,927 | $138,509 |
| + Debt | $110,358 | $72,675 | $40,809 | $510 |
| Enterprise Value | $135,977 | -$128,999 | $26,873 | -$54,825 |
| Revenue | $30,989 | $25,478 | $15,345 | $1,718 |
| % Growth | 21.6% | 66% | 793.2% | – |
| Gross Profit | $29,055 | $25,138 | $13,867 | -$48,788 |
| % Margin | 93.8% | 98.7% | 90.4% | -2,839.8% |
| EBITDA | -$125,497 | -$5,086 | -$95,527 | -$66,877 |
| % Margin | -405% | -20% | -622.5% | -3,892.7% |
| Net Income | -$141,405 | -$19,816 | -$101,660 | -$66,642 |
| % Margin | -456.3% | -77.8% | -662.5% | -3,879% |
| EPS Diluted | -2.63 | -0.51 | -2.77 | -2.44 |
| % Growth | -415.7% | 81.6% | -13.5% | – |
| Operating Cash Flow | -$118,001 | -$112,886 | -$55,477 | -$60,912 |
| Capital Expenditures | -$119 | -$1,774 | -$2,889 | $0 |
| Free Cash Flow | -$118,120 | -$114,660 | -$58,366 | -$60,912 |